A Synergic Potential of Antimicrobial Peptides against <i>Pseudomonas syringae</i> pv. <i>actinidiae</i>

• Main Authors: Nuno Mariz-Ponte, Laura Regalado, Emil Gimranov, Natália Tassi, Luísa Moura, Paula Gomes, Fernando Tavares, Conceição Santos, Cátia Teixeira
• Format: Article
• Language: English
• Published: MDPI AG 2021-03-01
• Series: Molecules
• Subjects: 3.1; <i>Actinidia</i> sp.; antimicrobial peptides; bacterial canker of kiwifruit; BP100; CA-M
• Online Access: https://www.mdpi.com/1420-3049/26/5/1461

<i>Pseudomonas syringae</i> pv. <i>actinidiae</i> (Psa) is the pathogenic agent responsible for the bacterial canker of kiwifruit (BCK) leading to major losses in kiwifruit productions. No effective treatments and measures have yet been found to control this disease. Despite antimicrobial peptides (AMPs) having been successfully used for the control of several pathogenic bacteria, few studies have focused on the use of AMPs against Psa. In this study, the potential of six AMPs (BP100, RW-BP100, CA-M, 3.1, D4E1, and Dhvar-5) to control Psa was investigated. The minimal inhibitory and bactericidal concentrations (MIC and MBC) were determined and membrane damaging capacity was evaluated by flow cytometry analysis. Among the tested AMPs, the higher inhibitory and bactericidal capacity was observed for BP100 and CA-M with MIC of 3.4 and 3.4–6.2 µM, respectively and MBC 3.4–10 µM for both. Flow cytometry assays suggested a faster membrane permeation for peptide 3.1, in comparison with the other AMPs studied. Peptide mixtures were also tested, disclosing the high efficiency of BP100:3.1 at low concentration to reduce Psa viability. These results highlight the potential interest of AMP mixtures against Psa, and 3.1 as an antimicrobial molecule that can improve other treatments in synergic action.